Previous Issue - Issue 64
Issue 64 | 2026
- Foreword
- Strategy
- Research & Development
- Clinical Trials
- Manufacturing
- Information Technology
- Expert Corner
- Advertorials
- BioPharma
- Go to Digital Magazine
Issue 64
PREVIOUS ISSUE
Foreword
Engaging Patients Earlier
The new strategic imperative for Asian Pharma
Clinical trials are undergoing a fundamental transformation For decades the success of a trial
Strategy
Elevating Drug Safety
Why quality case processing remains the backbone of pharmacovigilance
Every Individual Case Safety Report ICSR begins with a patient Behind every adverse event report is a person
Two Acts, One Geopolitical Moment
What the US BIOSECURE Act and EU Biotech Act mean for drug development in Asia-Pacific
Within hours of each other in December two pieces of legislation were enacted or proposed on opposite sides
Beyond Reporting
Safety surveillance analytics for medical devices (and therefore combination products) is imminent
The withdrawal of Bayers Essure permanent contraceptive device from global markets and the recall of DePuys ASR
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised?
As AIpowered adverse event processing becomes established within pharmacovigilance organisations
Complex Journey from Innovation to Patient impact
The pharmaceutical industry has never been more effective at developing innovative medicines Scientific breakthroughs
Research & Development
Long-acting Injectable Formulations
Recent development for suspensions based formulations
Longacting injectable LAI formulations are gaining considerable attention in modern pharmaceutics because they can maintain
Clinical Trials
Maximising Patient Engagement in Clinical Trials
Why early involvement is becoming a strategic imperative for Asian pharma
Clinical trials have traditionally been designed primarily by sponsors clinicians regulators and scientific experts
Manufacturing
Electronic Logs
The next phase of execution maturity in pharma
Electronic logs are now standard across pharmaceutical manufacturing operations They have strengthened traceability
Information Technology
From Snapshots to Movies
How AI is unlocking the continuous patient journey
Imagine trying to understand a sixmonth journey from a handful of photographs One photograph is taken at the beginning
Expert Corner
AI is in Every Pharma Strategy Deck
So why are decisions still taking so long?
The intent is no longer the challenge Most Pharma organisations are clear they want faster more confident
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
The emergence of D printing provides two distinct benefits in this area First researchers and formulators
Advertorials
LIPOSOMAL GENERICS IN ASIA
Supporting scalable drug delivery through GMP lipid excellence
Across Asia healthcare systems are balancing rising disease burden expanding access expectations and increasing
BioPharma
Clinically Validated Probiotics
Advantages, challenges, and the road ahead
The most commonly confused idea in the probiotics industry right now is that market growth equals category maturity
Why Sustainable Biomanufacturing Must Start Earlier in The Process
Sustainability is no longer a peripheral consideration in biomanufacturing It has become a strategic imperative
LYMPHOMA TREATMENT AT A CROSSROADS
The shift from CAR T Cells to T-Cell engagers
Two Distinct Technologies The distinction between CAR T and TCEs begins at the molecular level CAR T therapy is a form
